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Abstract
Background: Peri-operative radiation of retroperitoneal sarcomas (RPS) is an important component of multidisciplinary
treatment. All retrospective series thus far included patients treated with older radiation therapy (RT) techniques
including 2D and 3DRT. Intensity modulated radiation therapy (IMRT) allows for selective dose escalation while sparing
adjacent organs. We therefore report the first series of patients with RPS treated solely with IMRT, surgery and
chemotherapy. We hypothesized that IMRT would permit safe dose escalation and superior rates of local control (LC) in
this high-risk patient population.
Methods: Thirty patients with RPS treated with curative intent between 2006 and 2015 were included in this retrospective
study. RT was administered either pre- or post-operatively and IMRT was used in all patients. Statistical comparisons, LC,
distant metastasis (DM), and overall survival (OS) were calculated by Kaplan-Meier analysis and univariate Cox regression.
Results: Median follow-up time after completion of RT was 36 months (range 1.4-112). Median tumor size was 14 cm
(range 3.6 - 28 cm). The most prevalent histologies were liposarcoma in 10 (33%) patients and leiomyosarcoma in 10 (33%)
with 21 patients (70%) having high-grade disease. Twenty-eight (93%) patients had surgical resection with 47% having
positive margins. Chemotherapy was administered in 9 (30%) patients. RT was delivered pre-operatively in 11 (37%)
patients, and post-operatively in 19 (63%) with 60% of patients receiving a simultaneous integrated boost. Pre-operative
median RT dose to the high-risk area was 55 Gy (range, 43–66 Gy) while median post-operative dose was 60.4 Gy (range,
45-66.6 Gy). There was one acute grade 3 and one late grade 3 toxicity and no grade 4 or 5 toxicities. Three year actuarial
LC, freedom from DM, and OS rates were 84%, 64%, and 68% respectively. Positive surgical margins were associated
with a higher risk of local recurrence (p = 0.02) and decreased OS (p = 0.04). Pre-operative RT was associated with
improved LC (p = 0.1) with a 5-year actuarial LC of 100%. Administration of chemotherapy, timing of RT, histology or
grade was not predictive of OS.
Conclusions: Patients with RPS treated with peri-operative IMRT at our institution had excellent local control and low
incidences of toxicity.
Keywords: Soft tissue sarcoma, Retroperitoneum, Intensity modulated radiation therapy, Surgery, Radiation, Local
recurrence, Overall survival
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Background
Retroperitoneal sarcoma (RPS) represents a rare form of
heterogeneous soft tissue sarcoma that is challenging to
treat due to its deeply seated location and infiltrative
nature in the retroperitoneum. Surgical excision is the
mainstay of treatment and offers a potential cure when
wide resection margins are obtained. However, RPS
often presents late and has invaded nearby critical structures making complete excision extremely difficult. It
has been shown that incomplete resection and positive
microscopic margins predict death from disease and that
patients with incomplete resection have equally poor
survival as patients with unresectable disease [1]. Given
the difficulty in achieving local control, patients with
RPS most often die due to local progression, which is in
contrast to patients with extremity soft tissue sarcoma
who are more likely to die of distant disease [1, 2].
Improving local control is therefore crucial for improving overall survival in these patients.
Perioperative radiotherapy is often used to improve
local control, which ranges from 49 to 75% with surgery
and radiation therapy (RT) [3–7]. However, achieving
adequate dose and target coverage in the retroperitoneum is challenging due to the close proximity of
surrounding critical structures such as small bowel,
kidneys, liver and spinal cord. RT doses are often limited
to 45-50 Gy using older techniques and grade 3 or
greater toxicity can approach 40-50% even with these
suboptimal doses [8, 9]. Unfortunately, local recurrence
rates remain high even if doses of 50-55 Gy can be safely
administered with conventional RT [7, 9]. This implies
that bowel tolerant doses are not adequate for disease
control and that dose intensification is necessary for
improved local control. Intra-operative RT (IORT) has
been used to deliver a local boost to the margin at risk
resulting in improved LC but is also associated with
significant toxicity such as an 18% rate of grade 3 gastrointestinal obstruction and moderate to severe peripheral
neuropathy [9, 10].
Intensity modulated RT (IMRT) allows for selective
dose escalation with simultaneous integrated boosts to
high-risk areas while sparing dose to surrounding critical
structures. Use of IMRT in the management of RPS has
been previously reported [4, 11–13], but all retrospective
studies published thus far also included patients treated
using older techniques (2D or 3DRT) or with the
addition of IORT, which makes it difficult to determine
the outcomes with IMRT alone. Small prospective
studies have evaluated IMRT but these were in the preoperative setting only and were limited in their enrollment [14, 15]. The approach at Washington University
in St. Louis has been to use IMRT to treat the tumor or
tumor bed with bowel tolerant doses and then selectively
dose escalate to the margin at risk for recurrence, which

Page 2 of 10

is typically the posterior margin. We therefore aimed to
report our institutional experience of using IMRT with
simultaneous integrated boost either pre- or postoperatively in the management of RPS to determine
outcome as well as toxicity. To our knowledge this
represents the largest series of RPS treated solely with
peri-operative IMRT.

Methods
We retrospectively identified 30 patients with histologically confirmed soft tissue sarcoma of the retroperitoneum who were definitively treated with IMRT at
Washington University in St. Louis between 2006 and
2015. All medical records were reviewed in detail with
approval of the Institutional Review Board. All patients
underwent complete staging work-up including CT of
the chest, abdomen and pelvis. Patients with metastatic
disease at diagnosis, desmoid fibromatosis, prior
radiation therapy to the tumor, or treatment that was
palliative intent were excluded from this analysis.
All patients were evaluated and followed by a multidisciplinary team consisting of surgical, radiation, and
medical oncologists. Surgery involved resection of the
primary tumor as well as organs that appeared macroscopically involved or were enveloped by the tumor. The
decision to resect organs en bloc was made both radiographically and intra-operatively. Organs were not
resected if the tumor was thought to have a positive
margin in another location. The decision to administer
neoadjuvant or adjuvant chemotherapy was dependent
upon multiple factors including stage, histology, and
grade. Patients who developed metastatic disease after
definitive local treatment received salvage chemotherapy
per medical oncology discretion. These patients were
not considered to have received chemotherapy as a component of their definitive treatment.
Patients were referred for pre- or post-operative RT
based on the discretion of the evaluating surgeon and
discussions in a multi-disciplinary conference given concern for extent of anticipated positive margin. In general,
this decision was determined by considering factors that
influence patient outcomes such as histology, tumor size,
tumor depth and anatomic location. If the surgeons did
not believe they could achieve an R0 resection, and the
morbidity of radiation was thought to be acceptable,
then that patient would receive pre-operative RT and all
of these patients were considered for simultaneous integrated boost. Patients not referred for pre-operative RT
underwent surgery and if histology or margin status
provided an indication for RT, then post-operative RT
was performed. IMRT was delivered using either sliding
window technique or helical tomotherapy. All patients
underwent planning CT simulation. For pre-operative
RT, the gross tumor volume (GTV) consisted of the
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entire retroperitoneal sarcoma. In the case of postoperative RT, pre-operative imaging was fused to the
simulation CT to create the clinical target volume
(CTV), which included the resection bed (posterior margin) including areas with positive surgical margins while
avoiding organs that have settled into the post-operative
cavity. In all cases, the CTV was expanded beyond the
pre-operative GTV by 1.5 cm but respecting hard
borders such as bone and unaffected intra-abdominal
organs in the case of post-operative RT. Simultaneous
integrated boost was delivered to the area at high risk
for positive margins following surgical resection. This
includes areas where tumor was adjacent to the posterior abdominal wall, intra-abdominal organs, para- and
pre-vertebral spaces and major vessels. It is important to
note that the “high risk posterior margin” is subjective
and input from the surgeon is helpful. In patients who
received a simultaneous integrated boost, a high dose
was administered to the posterior tumor margin (CTV1)
and a second CTV was created (CTV2) which provided
a lower, bowel tolerant dose to a larger area at risk for
harboring microscopic disease (Fig. 1) as described [16, 17].
The planning target volume (PTV) consisted of a symmetric 0.5 cm margin beyond the CTVs. Daily imaging was
used for patient set-up. Organs at risk (OAR) including
spinal cord, kidneys, and bowel were contoured and classified as avoidance structures. The following dose constraints
and prescription details were used: 95% of prescription dose
should cover 95% of PTV; Small bowel max point dose
<54 Gy, V45 < 150 cm3, V55 < 1 cm3; Large bowel max
point dose <60 Gy, V30 < 200 cm3, V35 < 150 cm3, V45 <
100 cm3; Stomach max point dose <54 Gy; Liver max point
dose <50 Gy, mean < 20 Gy; Kidney V20 < 30% (combined
kidney dose); Spinal cord Dmax <45 Gy. Local failure (LF)
was defined as any disease recurrence located wholly or
partially within the radiation field. Distant metastasis (DM)
included disease in the lung, bone, or intra-abdominal

a
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organs outside of the radiation field. Follow-up times used
in the local control (LC), DM and overall survival (OS)
analyses were defined starting from the completion of
radiation therapy to the date of first occurrence of the
outcome of interest.
Patients were monitored for acute and late toxicity
using Common Terminology Criteria for Adverse Events
(CTCAE) v4.3 with data obtained by a radiation oncologist from electronic hospital records including weekly on
treatment visits and all follow-up visits.
Statistical analysis

The Kaplan-Meier method was used to calculate actuarial rates of overall survival, local control and distant
metastasis. The impact of clinical factors and patient
characteristics on LC, DM and OS was evaluated using
the log-rank test and univariate Cox proportional
hazards models. Multivariate analysis was not performed
given only one variable was significant on univariate analysis. All levels of significance were two-sided and p < 0.05
was considered statistically significant. SAS v9.4 was used
for statistical analysis.

Results
Patient and tumor characteristics

Patient and tumor characteristics are listed in Table 1.
The majority of patients (n = 27, 90%) were treated for
primary RPS, while only 3 patients (10%) were treated
for recurrent RPS that had been previously treated with
surgery alone. There were 15 males (50%) and 15 females
(50%) with a median age of 58.5 years (range 18-88 years).
Median tumor size was 14 cm (range 3.6 - 28 cm). The
majority of patients presented with AJCC stage III disease
(n = 18, 60%), followed by stage II (n = 7, 23%) and stage I
(n = 5, 17%). The most common histologies were liposarcoma (n = 10, 33%, which included de-differentiated liposarcoma (n = 5), well differentiated liposarcoma (n = 2),

b

Fig. 1 Contours and IMRT treatment plan with a simultaneous integrated boost for a patient with RPS treated with post-operative radiation therapy. a
Contours on a representative simulation computed tomography scan. Red contour represents the high risk posterior margin that will receive a high
dose (CTV1), while the green contour represents CTV2, which provides a lower, bowel tolerant dose to a larger area at risk. b IMRT treatment plan with
isodose lines. Contours the same as above (red contour = CTV1, green contour = CTV2). The volume receiving 6300 cGy is green, while the lower dose
volumes, 5250 cGy and 4200 cGy are yellow and blue respectively
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Value (%)

4 (13%) had low grade and grade was not able to be
determined in 1 (3%) patient.

Median

58.5

Treatment

Range

18-88

Table 1 Patient and tumor characteristics
Variable
Age (years)

Sex
Male

15 (50)

Female

15 (50)

Race
Caucasian

24 (80)

African-American

4 (13)

Asian

2 (7)

Tumor size (cm)
Median

14

Range

3.6-28

Stage
IA

1 (3)

IB

4 (13)

IIA

2 (7)

IIB

5 (17)

III

18 (60)

Histology
Liposarcoma

10 (33)

Leiomyosarcoma

10 (33)

Other

10 (33)

Tumor Grade
Grade 1

4 (13)

Grade 2

4 (13)

Grade 3

21 (70)

Unknown

1 (3)

Surgical margins
R0

12 (40)

R1

12 (40)

R2

2 (7)

Unknown

4 (13)

Chemotherapy
Yes

9 (30)

No

21 (70)

liposarcoma NOS (n = 1), pleomorphic liposarcoma (n = 1)
and inflammatory liposarcoma (n = 1)), and leiomyosarcoma (n = 10, 33%). Other histologies were analyzed as one
group and included 2 undifferentiated pleomorphic
sarcoma (UPS), 2 malignant peripheral nerve sheath
tumors, 1 angiosarcoma, 1 PNET/Ewings, 1 mesenchymal
chondrosarcoma, 2 malignant spindle cell neoplasms, and
1 sarcoma NOS. The majority of patients had high-grade
tumors (n = 21, 70%), while 4 (13%) had intermediate grade,

All patients underwent evaluation for resection of
primary or recurrent disease. Two patients did not
receive surgery due to low chance of obtaining negative
surgical margins and likelihood of significant morbidity.
Thus 28 patients (93%) underwent surgery as a main
component of their treatment. Adjacent organs that
showed evidence of invasion were resected en bloc in 17
patients (57%) and vascular resection and reconstruction
was performed when necessary. There were no postoperative deaths. Final surgical margins were negative
(R0) in 12 patients (40%), microscopically positive (R1)
in 12 patients (40%), grossly positive (R2) with residual
disease in 2 patients (7%), and could not be determined
in 4 patients (13%). Only 3/11 patients (27%) who
received pre-operative RT achieved negative margins at
the time of surgery.
All patients received photon radiotherapy using IMRT
technique though one patient received a mixed photon/
proton plan. One patient required surgical placement of
a tissue expander prior to RT, which consisted of two
saline implants placed in a Vicryl mesh in order to
decrease dose to bowel which had settled into the
postoperative renal bed. This implant was removed
1 month after RT with no complications. Eighteen (60%)
patients received simultaneous integrated boosts to the
margin at risk (Table 2). Radiation was administered
pre-operatively to 11 patients (37%) and post-operatively
to 19 patients (63%). The median dose delivered to the
high-risk margin (CTV1) was 55 Gy (range 43.12 – 66 Gy)
pre-operatively and 60.4 Gy (range 45 – 66.6 Gy) postoperatively with fractionation ranging from 180 to 220 cGy
per fraction. Overall, 40% of patients received greater than
62.5 Gy to the high-risk margin. In those patients receiving
a simultaneous integrated boost, the median dose to areas
at risk (CTV2) was 50 Gy (range 45-56 Gy) (Table 2).
A total of 9 patients (30%) received chemotherapy. Of
these patients, 4 patients (44%) received chemotherapy
neoadjuvantly (2 patients received epirubicin and ifosfamide and 2 received vincristine, doxorubicin and cyclophosphamide) and 5 patients (56%) were treated with
adjuvant chemotherapy (1 received gemcitabine and
taxotere while 4 received epirubicin and ifosfamide).
Survival and patterns of failure

The median follow-up was 36.3 months (range 1.4 –
112 months). A total of 13 patients (43%) had died at
last follow-up and actuarial 3 and 5 year OS was 68%
and 50% respectively (Fig. 2a). Timing of radiotherapy,
histology, tumor grade and treatment with chemotherapy were not associated with OS (Table 3). Surgical
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Table 2 Timing, dose, and characteristics of IMRT treatment
Variable

Value (%)

a

IMRT
Pre-operative RT

11 (37)

Post-operative RT

19 (63)

Simultaneous integrated boost

18 (60)

Radiation dose to high risk area, PTV1 (Gy)
Pre-operative
Median

55

Range

43-66

Post-operative
Median

60.4

Range

45-66.6

b

Radiation dose to low risk area, PTV2 (Gy)
Median

50

Range

45-56

margin status, however, was correlated with OS as
patients with negative margins had 3- and 5-year OS of
92% and 78% while those with positive margins (R1) had
3- and 5-year OS of 52% and 35% respectively (p = 0.09).
R1 resection was significantly associated with OS on
univariate cox analysis (p = 0.04) though this should
be interpreted with caution given the small numbers
in this study.
A total of 5 patients (17%) experienced LF and 3and 5-year actuarial LC was 84% and 79% respectively
(Fig. 2b). All patients who failed locally received RT
post-operatively. LC in this group was 77% and 69% at
3 and 5 years while patients who received preoperative RT had 100% LC at 3 and 5 years (p = 0.1,
Fig. 3a). LF occurred despite a high dose to the highrisk margin. Three of five patients with LF received
63-66.6 Gy, while the other two patients received 50
and 45 Gy. Surgical margin status was a statistically
significant predictor of LC. Patients who received an
R0 resection had 100% LC at 3 and 5 years whereas
patients receiving an R1 resection had 79% and 60%
LC at 3 and 5 years respectively (p = 0.018, Fig. 3b).
Both patients with an R2 resection failed locally and
died within 2 years of treatment. Patients with low
grade (grade 1-2) tumors had 100% LC at 3 and
5 years, while patients with high grade tumors had
77% and 68% LC at 3 and 5 years respectively (p =
0.09). Tumor histology was also associated with local
control as patients with leiomyosarcoma had 100% LC
at both 3 and 5 years, while patients with liposarcoma
had 100% and 75% LC at 3 and 5 years respectively. Patients with other histologies did worse overall and had a
58% LC at both 3 and 5 years (p = 0.059, Fig. 3c). No clinical variables were significantly correlated with LC on

c

Fig. 2 Kaplan-Meier curves for (a) overall survival, (b) local control,
and (c) distant metastasis for all patients with RPS treated with IMRT

univariate analysis. Importantly, all patients that failed locally had died at last follow-up.
Overall, 13 patients (43%) failed distantly. The actuarial rate of DM at 3 and 5 years was 36% and 47%
respectively (Fig. 2c). The most common first site of DM
was lung in 46% of patients followed by liver (23%) and
abdominal sites outside of the radiation field (23%). Sites
of DM after the first metastatic occurrence included
lung in 10/13 (77%) patients, liver in 5/13 (38%)
patients, and other intra-abdominal sites in 4/13 (31%)
patients. Of note all patients that developed liver

Cosper et al. Radiation Oncology (2017) 12:198

Page 6 of 10

Table 3 Univariate log-rank analysis of IMRT timing, surgical
margin status, chemotherapy, histology, and tumor grade on
OS, LC and DM
3-year rate (%)

5-year rate (%)

Table 3 Univariate log-rank analysis of IMRT timing, surgical
margin status, chemotherapy, histology, and tumor grade on
OS, LC and DM (Continued)

p value

Overall Survival

3-year rate (%)

5-year rate (%)

p value

Chemotherapy

Radiation therapy
Pre-operative RT

80

54

Post-operative RT

62

48

0.85

92

78

Positive (R1)

52

35

Yes

67

53

No

69

48

LMS

77

58

Liposarcoma

67

50

Other

60

45

Low

86

57

High

65

50

55

55

No

26

44

LMS

50

50

Liposarcoma

11

33

Other

40

55

Low

25

40

High

40

49

0.69

Histology

Surgical Margins
Negative (R0)

Yes

0.09

Chemotherapy

0.53

Grade
0.74

0.54

Histology
0.48

Grade
0.58

Local Control
Radiation therapy
Pre-operative RT

100

100

Post-operative RT

77

69

Negative (R0)

100

100

Positive (R1)

79

60

Yes

65

65

No

94

85

LMS

100

100

Liposarcoma

100

75

Other

58

58

Low

100

100

High

77

68

Pre-operative RT

32

55

Post-operative RT

38

45

Negative (R0)

25

34

Positive (R1)

27

45

0.10

Surgical Margins
0.02

Chemotherapy
0.16

metastasis at any time had intraparenchymal metastasis
indicating hematologic spread. Overall rate of DM did
not differ between patients receiving RT pre- or postoperatively and was 32% and 38% at 3 years and 55%
and 45% at 5 years respectively however, all patients who
developed metastasis to intra-abdominal sites outside of
the radiation field received post-operative RT indicating
that pre-operative RT may reduce the risk of intraabdominal spread. Extent of surgical resection, grade,
histology, and treatment with chemotherapy did not
affect the incidence of DM (Table 3). No clinical variables were significantly correlated with DM on univariate analysis. DM was not associated with LR as 9/13
patients (69%) developed DM without LR while only 4/
13 patients (31%) developed both LR and DM. Overall,
77% of patients who developed DM had died at last
follow-up.
Toxicity

Histology
0.06

Grade
0.09

Distant Metastasis
Radiation therapy
0.91

Surgical Margins
0.16

Only two patients (7%) developed Grade 3 toxicities.
One patient who received pre-operative RT developed
acute grade 3 nausea/vomiting requiring intravenous
hydration and her treatment was discontinued after
43 Gy (out of a planned 49 Gy). Another patient
developed a duodenal stricture 6 months after postoperative RT (50.4 Gy), which required dilation. There
were no grade 4 or 5 toxicities.

Discussion
Treatment of RPS remains extremely challenging and
long-term overall survival remains poor despite advances
in surgical and radiotherapy technique. Local recurrence
has historically been the predominant failure pattern in
patients with RPS and accounts for the majority of
deaths [1, 7, 18]. Conversely, our series with IMRT
revealed that most patients died due to DM with few LF,
however all patients with a LF died of disease. This may
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b

c

Fig. 3 Kaplan-Meier curves for local control for patients with RPS stratified by (a) pre-operative (pre-op, red) versus post-operative (post-op, blue)
RT, (b) surgical margin status, and (c) histology. Surgical margin status was significantly associated with local control (p = 0.018)

be explained by the ability to selectively dose escalate to
high-risk margins with IMRT, which was not possible
using older radiotherapy techniques. Similar results were
found in a randomized trial comparing EBRT with or
without an IORT boost where IORT improved LC but
had higher rates of DM [9]. Though our data reveals that
IMRT is able to achieve excellent LC, it did not translate
into improved OS compared to other published series.
This is likely due to the incidence of DM, which is slightly
higher than previously reported experiences [4, 6].
Perhaps the improved LC led to increased short-term
survival which allowed time for development of DM.
Interestingly, the majority of patients with DM did not
have a LR which implies the need for better and perhaps
more aggressive systemic therapy.
IMRT allows for selective dose escalation to high-risk
margins while allowing for maximal sparing of OAR and
has been employed pre-operatively in a small series with
excellent LC [15] and is currently being evaluated in a
clinical trial (NCT01841047). Using a simultaneous integrated boost, we were able to achieve even higher doses
to the margin at risk since over 40% of patients received
greater than 62.5 Gy to CTV1. This resulted in excellent

5-year local control of 79%, which is superior to most
other published series. However, three of the five
patients who failed locally received 63, 66, and 66.6 Gy
post-operatively. Failure therefore occurred despite a
high dose to the high-risk margin, implying inherent
radioresistant biology of some sarcomas, which may
require further dose escalation, or tumor infiltration
beyond the target. However all of these patients had
high-grade disease, two had microscopically positive
margins and one had gross residual disease, reinforcing
the importance of a complete resection. Indeed, we
revealed that surgical margin status was the only factor
significantly associated with both LC and OS on logrank test and univariate analysis respectively as has been
shown in numerous prior studies [3, 4, 7]. Given that LR
occurred in patients with positive margins despite high
doses of radiation, it appears that high doses of RT
cannot compensate for inadequate surgery. Proton
therapy also allows for local dose escalation with
minimal toxicity and a phase I dose escalation trial in
the pre-operative setting has shown promising results
[19]. A phase I/II dose escalation trial comparing preoperative IMRT and intensity modulated proton therapy
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(IMPT) is currently accruing (NCT01659203) and will
provide insight into determining the safest and most
efficacious radiation modality.
Though higher doses are historically associated with improved LC [5, 18], they come at the cost of greater toxicity.
Historically, conventional EBRT is associated with a high
rate of grade 3 or greater gastrointestinal toxicity [3, 9, 13]
though this rate has been decreasing with more advanced
technology [4, 13]. Intra-operative RT (IORT) and brachytherapy have been used to provide a local boost to the
high-risk margin while sparing surrounding organs though
is technically difficult and is also associated with significant
side effects including debilitating neuropathy which ranges
from 6 to 33% and an 18-30% rate of severe, grade 3-4 GI
side effects [9, 10, 20]. IMRT allows the dose to conform
more precisely to the three-dimensional shape of the tumor
while minimizing dose to the surrounding critical
structures allowing local dose escalation with fewer
side effects. Our results compare favorably to the LC
rates achieved with IORT but with less toxicity.
There is retrospective evidence that IMRT provides a
dosimetric advantage and is associated with significantly
less toxicity than 3DRT [13, 21]. Here we report a grade
3 toxicity rate of 7% using IMRT. Interestingly, the two
patients with grade 3 toxicities received low doses (43
and 50.4 Gy) of radiation implying that perhaps their
biology rather than the dose was involved in the development of toxicity. No patients who received greater
than 50.4 Gy experienced a grade 3 toxicity implying we
were able to adequately spare OAR using our technique
with IMRT and simultaneous integrated boost.
There have been no randomized prospective trials
comparing pre- to post-operative RT but pre-operative
radiation has become the modality of choice for large,
high grade RPS as this increases the likelihood of
achieving a resection with negative margins [22] and is
associated with less toxicity [3, 4]. Our results reveal that
patients who received pre-operative RT had 100% LC at
both 3 and 5 years which supports the use of IMRT in
the pre-operative setting. Interestingly, patients receiving
pre-operative RT had a low rate of negative surgical
margins which is likely explained by the patient population that was selected for this modality in the first place;
namely patients with less favorable tumor characteristics
with a low chance of obtaining negative surgical margins. There was no difference in toxicity between patients who received pre- or post-operative RT though
our toxicity rate was low which limits interpretation of
this result. Post-operative RT has historically been associated with higher acute and long-term morbidity but
our findings using IMRT do not support this as only 1/
19 patients (5%) receiving post-operative RT experienced
a grade 3 toxicity. Though pre-operative RT is currently
the modality of choice based upon several retrospective
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studies, we show here that using IMRT in the postoperative setting can achieve good LC with minimal
toxicity.
There are several limitations to this study that are inherent in most RPS studies. Our small sample size is due not
only to the rarity of this disease, but also the relatively
recent adoption of IMRT technique. Given the small sample size and low number of events, statistical significance
must be interpreted with caution and results may be
considered as positive associations rather than statistical
conclusions. Additional challenges with this dataset are
multiple histologies, variability in grade and tumor size,
and inclusion of patients with recurrent disease. Of the
three patients that were treated for recurrent disease, two
were treated with RT post-operatively, both of which died
of disease and one patient was treated pre-operatively and
had no evidence of disease at last follow-up. The small
number of patients and events in this study also limited
univariate and multivariate analysis. This study is retrospective in nature, and there is some bias regarding the
patients selected for RT and the timing of RT with surgery.
However, there is no inherent treatment bias with regard
to radiation technique as all patients treated with RT after
the year 2006 were treated with IMRT. A prospective,
randomized trial is required to fully investigate the proposed benefit of IMRT yet this is unlikely to occur given
the known dosimetric advantages and decreased toxicity
associated with IMRT over 3DRT.
In conclusion, though there is no randomized evidence
to support the use of peri-operative RT as a component of
definitive treatment of RPS there are several large retrospective series that reveal a benefit with RT. One of the largest multi-institutional retrospective series including over
1000 patients with RPS found that peri-operative
administration of RT was statistically significantly associated with improved LC [6], and recent analysis of the
NCDB and SEER databases revealed that peri-operative
radiotherapy was associated with a significant increase in
OS compared to patients who were treated with surgery
alone [23, 24]. We eagerly await the results of the phase 3
randomized trial (STRASS, NCT01344018) comparing surgery alone with pre-operative RT and surgery as this will
provide an answer as to whether RT improves recurrencefree survival.

Conclusions
Here we report for the first time a cohort of patients with
RPS treated solely with IMRT, which resulted in excellent
LC and low rates of toxicity compared to older series,
which all included patients treated with standard 2D, 3DRT
or IORT. However, positive surgical margins and highgrade disease continue to be poor prognostic factors regardless of the RT modality. With continued improvements
in radiotherapy technology the therapeutic ratio will
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hopefully continue to improve. Unfortunately, OS of patients with RPS remains poor, which emphasizes the need
for improved local and systemic therapy.
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